BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27530265)

  • 1. Does true Gleason pattern 3 merit its cancer descriptor?
    Miah S; Ahmed HU; Freeman A; Emberton M
    Nat Rev Urol; 2016 Sep; 13(9):541-8. PubMed ID: 27530265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease.
    Reichard CA; Klein EA
    Nat Rev Urol; 2017 Jan; 14(1):59-64. PubMed ID: 27898099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary grading for prostate cancer: implications for patient care.
    Brimo F; Montironi R; Egevad L; Erbersdobler A; Lin DW; Nelson JB; Rubin MA; van der Kwast T; Amin M; Epstein JI
    Eur Urol; 2013 May; 63(5):892-901. PubMed ID: 23092544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A concise update on prostate pathology.
    Xu W; Zhou M
    Cesk Patol; 2014; 50(4):120-8. PubMed ID: 25418898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
    Epstein JI; Egevad L; Amin MB; Delahunt B; Srigley JR; Humphrey PA;
    Am J Surg Pathol; 2016 Feb; 40(2):244-52. PubMed ID: 26492179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of changing definitions within the Gleason grading system.
    Lotan TL; Epstein JI
    Nat Rev Urol; 2010 Mar; 7(3):136-42. PubMed ID: 20157302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in prostate cancer pathology: Gleason grading and beyond.
    Shah RB; Zhou M
    Pathol Int; 2016 May; 66(5):260-72. PubMed ID: 26991008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gleason grading: past, present and future.
    Delahunt B; Miller RJ; Srigley JR; Evans AJ; Samaratunga H
    Histopathology; 2012 Jan; 60(1):75-86. PubMed ID: 22212079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
    Epstein JI; Amin MB; Reuter VE; Humphrey PA
    Am J Surg Pathol; 2017 Apr; 41(4):e1-e7. PubMed ID: 28177964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary Gleason grading and novel Grade Groups in clinical practice.
    Magi-Galluzzi C; Montironi R; Epstein JI
    Curr Opin Urol; 2016 Sep; 26(5):488-92. PubMed ID: 27308734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grading of Prostate Cancer: Past, Present, and Future.
    Matoso A; Epstein JI
    Curr Urol Rep; 2016 Mar; 17(3):25. PubMed ID: 26874537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation.
    Egevad L
    Anal Quant Cytol Histol; 2008 Aug; 30(4):190-8. PubMed ID: 18773736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Tumor Oxygenation Tested by Magnetic Resonance Imaging (MRI) in Prostate Cancer Grading.
    Geng H; Tong W; Han F; Zhu K; Cao Y; Chen X
    Med Sci Monit; 2019 Apr; 25():2505-2510. PubMed ID: 30950457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of the International Society of Urological Pathology modified Gleason grading system.
    Egevad L; Mazzucchelli R; Montironi R
    Arch Pathol Lab Med; 2012 Apr; 136(4):426-34. PubMed ID: 22458905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gleason inflation 1998-2011: a registry study of 97,168 men.
    Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
    BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncological Outcomes After Radical Prostatectomy for High-Risk Prostate Cancer Based on New Gleason Grouping System: A Validation Study From University of Southern California With 3,755 Cases.
    Djaladat H; Amini E; Xu W; Cai J; Daneshmand S; Lieskovsky G
    Prostate; 2017 May; 77(7):743-748. PubMed ID: 28144967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
    Voss J; Pal R; Ahmed S; Hannah M; Jaulim A; Walton T
    BJU Int; 2018 Jun; 121(6):863-870. PubMed ID: 29239082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation.
    Srigley JR; Delahunt B; Samaratunga H; Billis A; Cheng L; Clouston D; Evans A; Furusato B; Kench J; Leite K; MacLennan G; Moch H; Pan CC; Rioux-Leclercq N; Ro J; Shanks J; Shen S; Tsuzuki T; Varma M; Wheeler T; Yaxley J; Egevad L
    Pathology; 2019 Aug; 51(5):463-473. PubMed ID: 31279442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
    Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
    Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
    Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.